QIAGEN price target raised to $26 from $20 at RW Baird Baird raised its price target on QIAGEN following better than expected Q4 results. The firm cited higher guidance, tangible drivers of organic growth, and cash available for accretive use. Shares are Outperform rated.
QIAGEN downgraded to Sell from Neutral at Goldman Goldman downgraded QIAGEN to Sell based on a mixed growth outlook for new products and the dilutive impact on the core franchise value from M&A. Price target lowered to $19 from $21.